Close
MTRG-banner

MTRG Projects

Find out more about consulting projects completed by the Medical Technology Research Group

We provide high quality consulting services to pharmaceutical companies and other organisations, collaborating with Market Access, HTA, Pricing, Policy and Government Affairs teams

Dr Jennifer Gill, Associate Director, MTRG

NGS Value Framework Template

A collaborative value framework to assess Next-Generation Sequencing/Comprehensive Genomic Profiling diagnostic technologies

Ongoing

Client: Precision Cancer Consortium

Find out more here.

Sustainable-Healthcare-Financing-for-SDG3-in-ASEAN-6-report-cover

Sustainable Healthcare Financing for SDG-3 in ASEAN-6

February 2024

Client: US-ASEAN Business Council  

Find out more here. 

Determining-the-Benefits-of-Improving-Secondary-Prevention-of-Cardiovascular-Disease-Report-Cover

Determining the Benefits of Improving Secondary Prevention of Cardiovascular Disease

November 2023

Client: EFPIA Cardiovascular Health Platform

Find out more here.

The-Promise-of-Population-Health-Management-in-England

Population Health Management in England

October 2022

Client: Novartis 

Find out more here. 

Towards-better-outcomes-in-autism-by-addressing-policy-change

Outcomes in Autism

October 2022

Client: F. Hoffmann La Roche

Find out more here.

Access-to-medicines-in-Europe

Access to Medicines in Europe

November 2021

Client: MSD

Find out more here. 

The-Role-of-Virtual-Health-Care-and-the-Pharmaceutical-Sector-in-Improving-Population-Health

Population Health and Virtual Care

June 2021

Client: Sanofi 

Find out more here. 

PhRMA-Headroom-Front-Cover

Headroom for Innovation in Egypt and the Kingdom of Saudi Arabia

May 2021

Client: PhRMA

Find out more here. 

Severe-Asthma

Severe Asthma

May 2021

Client: AstraZeneca

Find out more here. 

Predictive-Analytic-Techniques

Predictive Analytic Tools and Value-Based Healthcare

February 2021

Client: Takeda

Find out more here. 

Indication-Based-Pricing-of-Innovative-Medicines

Indication-Based Pricing of Innovative Medicines

October 2020

Client: Novartis 

Find out more here. 

Personalised-Oncology-in-Europe

Access to Personalised Oncology in Europe 

November 2020 

Client: EFPIA

Find out more here. 

Financing-High-Cost-Curative-Therapies

Financing High-Cost Curative Therapies

October 2020

Client: Novartis

Find out more here. 

Latin-America-Healthcare-System-Overview

Latin American Health System Overview

August 2019

Client: F. Hoffmann La Roche

Find out more here. 

Pharmaceutical-Policy-in-China

Pharmaceutical Policy in China

May 2019

Client: Gilead Sciences

Find out more here. 

The-use-of-Real-World-Evidence-–-Opportunities-for-Europe

The Use of Real World Evidence

November 2016 - December 2019

Client: F. Hoffmann La Roche

Find out more here. 

 

Pharmaceutical-Pricing-and-Reimbursement-in-the-Middle-East

Pharmaceutical Pricing and Reimbursement in the Middle East and North Africa Region

November 2018

Client: PhRMA

Find out more here. 

Changing-paradigms-in-the-management-of-Multiple-Sclerosis

Changing paradigms in the management of Multiple Sclerosis

November 2018

Client: F. Hoffmann La Roche

Find out more here. 

Accelerated-Approval-and-Access-Schemes

Accelerated Approval and Access Schemes - New Oncology Medicines

May 2017 – November 2019

Client: AstraZeneca

Find out more here. 

European-survey-on-the-use-of-Real-World-Evidence

European survey on the use of Real World Evidence

January 2017 - May 2018

Client: F. Hoffmann La Roche

Find out more here. 

External-Reference-Pricing-within-and-across-countries

External Reference Pricing

January 2016 - November 2017

Client: Pfizer

Find out more here. 

Improving-Outcomes-for-People-with-MS

Improving Outcomes for People with Multiple Sclerosis

October 2017

Client: F. Hoffmann La Roche

Find out more here. 

Improving-Access-to-Contraception

Improving Access to Contraception

September 2017 

Client: Pfizer

Find out more here. 

Study-on-impact-analysis-of-policy-options-for-strengthening-EU-cooperation-on-Health-Technology-Assessment-HTA

Policy Options for strengthened EU cooperation on Health Technology Assessment (HTA)

August 2017

Client: European Commission

Find out more here. 

Share

PillsBannerUnsplash

Learn more about MTRG

PexelTeamPhoto

Meet the MTRG Team

PexelsLibrary

MTRG Publications and Reports

PublicationsUnsplash

MTRG Grants

More from LSE Health

Check back later for our latest Twitter updates.

Contact us

Telephone

+ 44 (0) 20 7955 6840

Email

lse_health@lse.ac.uk

Address

LSE Health, Cowdray House, London School of Economics and Political Science, Houghton Street, London WC2A 2AE

Follow us

LinkedIn Twiiter